



Effects of smoking, gender and occupational exposures on the risk of severe pulmonary fibrosis: a population based case-control study

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-004018
Article Type:	Research
Date Submitted by the Author:	13-Sep-2013
Complete List of Authors:	Ekström, Magnus; Department of Clinical Sciences, Division of Respiratory Medicine & Allergology, Lund University, ; Department of Medicine, Blekinge Hospital, Gustafson, Torbjörn; Institution of Public Health and Clinical Medicine, Umeå University, Boman, Kurt; Institution of Public Health and Clinical Medicine, Umeå University, Nilsson, Kenneth; Respiratory Medicine Unit, Department of Medicine Solna, the Karolinska Institute and Karolinska University Hospital, Tornling, Göran; Respiratory Medicine Unit, Department of Medicine Solna, the Karolinska Institute and Karolinska University Hospital, Murgia, Nicola; Section for Occupational Medicine, Respiratory Diseases and Toxicology, University of Perugia, Toren, Kjell; Section for Occupational and Environmental Medicine, Institute of Medicine, Sahlgrenska Academy at the University of Gothenburg,
Primary Subject Heading:	Respiratory medicine
Secondary Subject Heading:	Epidemiology, Occupational and environmental medicine, Smoking and tobacco
Keywords:	Epidemiology < TROPICAL MEDICINE, Thoracic medicine < INTERNAL MEDICINE, Interstitial lung disease < THORACIC MEDICINE

SCHOLARONE™
Manuscripts

1
2
3 **Effects of smoking, gender and occupational exposure on the risk of severe pulmonary**
4 **fibrosis: a population based case-control study**
5
6
7

8 Magnus Ekström, MD, PhD^{1,2}; Torbjörn Gustafson, MD, PhD³; Kurt Boman, MD, PhD³;
9
10 Kenneth Nilsson, MD, PhD³; Göran Tornling, MD, PhD⁴; Nicola Murgia, MD⁵; Kjell Torén,
11
12 MD, FCCP, PhD⁶
13
14
15
16
17

18
19 ¹ Department of Clinical Sciences, Division of Respiratory Medicine & Allergology, Lund
20 University, SE-22100 Lund, Sweden
21
22

23
24 ² Department of Medicine, Blekinge Hospital, SE-371 85 Karlskrona, Sweden
25
26

27 ³ Institution of Public Health and Clinical Medicine, Umeå University, SE-901 85 Umeå,
28 Sweden
29
30

31
32 ⁴ Respiratory Medicine Unit, Department of Medicine Solna, the Karolinska Institute and
33 Karolinska University Hospital, SE-171 76 Solna, Sweden
34
35

36
37 ⁵ Section for Occupational Medicine, Respiratory Diseases and Toxicology, University of
38 Perugia, 06123 Perugia, Italy
39
40

41
42 ⁶ Section for Occupational and Environmental Medicine, Institute of Medicine, Sahlgrenska
43 Academy at the University of Gothenburg, SE-405 30 Gothenburg, Sweden
44
45

46
47 **Corresponding author:** Magnus Ekström, Department of Respiratory Medicine, Blekinge
48 Hospital, SE-371 85 Karlskrona, Sweden. E-mail: pmekstrom@gmail.com. Tel: +46
49 455731000.
50
51
52

53
54
55 **Keywords:** Pulmonary fibrosis; Smoking; Occupational exposure; Mortality; Gender
56
57
58
59
60

1
2
3 **Running title:** Interacting factors and severe pulmonary fibrosis
4
5

6 **Word count:** 1,865
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3 Word count of abstract: 198
4

5 **ABSTRACT**
6
7

8 **Objectives:** To estimate the effects of smoking, gender and occupational exposure on the risk
9
10 of developing severe pulmonary fibrosis (PF), including dose-response and interaction effects.
11

12
13 **Methods:** National case-control study of 171 patients (cases) starting long-term oxygen
14
15 therapy (LTOT) for PF in Sweden between February 1997 and April 2000, and 719 random
16
17 control subjects from the general population. Of cases, 137 had probable idiopathic
18
19 pulmonary fibrosis (IPF). The odds ratios (ORs) for smoking, gender, and occupational
20
21 exposure were estimated using Mantel-Haenzel analysis and conditional logistic regression,
22
23 controlling for age and year of diagnosis.
24
25

26
27 **Results:** The adverse effect of smoking was amplified by male gender and occupational
28
29 exposure, OR 4.6 ([95% confidence interval] 2.1 – 10.3) for PF, and OR 3.0 (1.3 – 6.5) for
30
31 IPF, compared to in non-exposed women. Higher cumulative smoking exposure was linearly
32
33 associated with increased risks. Compared to smoking less than ten pack-years, smoking ≥ 20
34
35 pack-years was associated with increased risk of PF and IPF, OR 2.6 (1.4 – 4.9) and OR 2.5
36
37 (1.3 – 5.0), respectively.
38
39

40
41 **Conclusion:** Smoking has a dose-related association with increased risk of severe PF. Men
42
43 with a history of smoking and occupational exposure is a particular risk group for developing
44
45 severe pulmonary fibrosis.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ARTICLE SUMMARY

Article focus

- Smoking, male gender and occupational exposures are proposed risk factors for developing severe idiopathic pulmonary disease (IPF), but data on the interplay between these factors are limited.
- This study aims to estimate the effects of smoking, gender and occupational exposure on the risk of developing severe IPF, including interactions and dose-response effects.

Key messages

- Smoking has a dose-response association with increased risk of severe IPF.
- The adverse effect of smoking is strongly amplified by male gender and occupational exposure. This study identifies men with a history of smoking and occupational exposures as a particular risk group for developing severe IPF.

Strengths and limitations

- Population-based case-control study of subjects developing oxygen-dependent pulmonary in Sweden with randomly selected controls from the general population.
- Analysis of detailed exposure data, accounting for confounders and lag time between exposure and disease.
- As the underlying etiology may be difficult to ascertain in patients with oxygen-dependent pulmonary fibrosis, IPF was defined through review of national administrative register data and individual medical records.

BACKGROUND

Pulmonary fibrosis (PF) constitutes a range of conditions that are either secondary to diseases or factors, such as systemic inflammatory disease and drug therapies, or primary, of which the most common is idiopathic pulmonary fibrosis (IPF).¹

IPF is a chronic, progressive, fibrosing interstitial lung disease with a high risk of rapid progression and mortality.² Median survival after diagnosis is approximately two years.² The incidence of IPF has increased over time, with marked regional differences suggesting the pathogenic role of various environmental and occupational exposures.³

The etiology of IPF remains unknown.² The majority of IPF patients are men with a history of current or past smoking.² Most case-control studies have suggested an association between smoking and an increased risk of IPF,⁴⁻⁷ although one study reported no such association.⁸

This inconsistency is most likely due to differences in study settings, the included covariates and, in some studies, the use of hospital patients as control subjects, which might have biased the smoking estimates.^{4 7 9-11} Occupational exposures, including metal, stone and wood dust, have been linked to higher risks of developing IPF.¹²

It is unknown if there are interactions between smoking, gender and occupational exposure, and the risk of developing IPF. The only two studies which analyzed interactions reported a tendency towards an amplified IPF risk in patients with a history of smoking and occupational exposure, but the studies failed to establish statistically significant interactions.^{6,13} Moreover, it is unclear if smoking really is an etiologic factor for IPF, as studies included low numbers of patients, and data on whether there is a dose-dependent relation between smoking and the risk of IPF are limited.

1
2
3 The aim of the present nationwide case-control study was therefore to estimate the
4
5 associations between smoking, gender, occupational exposure, and the risk of developing
6
7 severe pulmonary fibrosis.
8
9

16 **METHODS**

19 This was a national, register-based case-control study. Patients starting long-term oxygen
20
21 therapy (LTOT) for PF between 1 February 1997 and 4 April 2000 in the national Swedevox
22
23 register were eligible for inclusion as cases. The Swedevox register covers some 85% of all
24
25 patients starting LTOT in Sweden.¹³ Details of the study design and a previous analysis using
26
27 the same data set have been published.¹⁴ Data was collected through an extensive postal
28
29 questionnaire on smoking, occupational exposure (including fibers, fumes, gas, mineral dust,
30
31 organic dust, and vapours) and diagnosis of PF. The questionnaire has been described in detail
32
33 elsewhere.¹⁵ Smoking data included the year of starting smoking, date of stopping smoking,
34
35 and the mean number of smoked cigarettes per day during each ten year period between ages
36
37 15 – 65 years, and the mean exposure after 65.¹⁵ After the exclusion of patients who were
38
39 incorrectly registered (n = 12; 5%) or did not respond to the questionnaire (n=58; 24%), 171
40
41
42
43
44 PF cases were included in the analysis.

45
46 Patients with probable idiopathic pulmonary fibrosis (IPF cases, n = 137) were identified
47
48 through a review of each patient's medical record done independently by specialists in
49
50 respiratory medicine (KN, TG).¹⁴ IPF cases in the study included only patients without any
51
52 identifiable or probable cause of PF (infection, pneumoconiosis, medications, irradiation,
53
54 rheumatic or systemic inflammatory diseases etc.)¹⁴
55
56
57
58
59
60

1
2
3 Control subjects were selected as a random sample (n = 1000) from the general population of
4
5 the same age range as the PF patients. Of the control subjects, 719 (72%) returned complete
6
7 exposure data and were included in the analysis.
8
9

10 11 12 13 **Ethics Statement**

14
15
16 All participants gave their informed consent to participate. The study was approved by all the
17
18 relevant ethics committees in Sweden, the Swedish National Board of Health and Welfare,
19
20 and the Data Inspection Board.
21
22

23 24 25 26 27 **Statistical Analysis**

28
29
30 Cases and control subjects were categorized according to year of birth (1906 – 1923, 1924 –
31
32 1936 or 1937 – 1969) and cases according to year they received their PF diagnosis (1968–
33
34 1986, 1987–1993 or 1994–1999). Control subjects were assigned a time point corresponding
35
36 to the year patients received their PF diagnosis, using a method described previously.^{14 15}
37

38
39 First, control subjects within each birth year group were assigned a random diagnosis year
40
41 group, weighted by the number of cases in each diagnosis year group. Then, the year of PF
42
43 diagnosis of each control subject was set to the mid-year of the corresponding year of the
44
45 patient group. Characteristics at baseline (the date the questionnaire was filled in) were
46
47 presented using frequencies and percentages for categorical variables. Continuous data were
48
49 presented using mean with standard deviation (SD) and median with range or interquartile
50
51 range (IQR) for variables with normal and skewed distribution, respectively.
52
53

54
55 Smoking status and cumulative smoking exposure, calculated as pack years ([mean number of
56
57 cigarettes per day] / 20 x [years of exposure]), were recorded up to 10 years prior to the date
58
59
60

1
2
3 of the PF diagnosis (a 10-year time lag), allowing time between smoke exposure and the
4
5 development of oxygen-dependent PF.
6
7

8 Associations between smoking and the risk of developing oxygen-dependent PF and IPF, and
9
10 the interactions between smoking, occupational exposure and gender were estimated and
11
12 reported using Mantel-Haenzel analysis, controlling for year of birth, year of diagnosis and
13
14 gender, as applicable. Interactions were also analyzed using conditional logistic regression,
15
16 stratified for year of birth, year of diagnosis, gender, with adjustment for age and pack-years
17
18 of smoking. All estimates were consistent between Mantel-Haenzel analysis and the
19
20 conditional logistic models.
21
22

23
24 Associations were expressed as odds ratios (ORs) with 95% confidence intervals (CIs).
25
26 Statistical significance was defined as a double-sided $p < 0.05$. Statistical analyses were
27
28 performed using Stata version 11.1 (StataCorp LP; College Station, TX) and SAS version 9.2
29
30 (SAS Institute, Inc., Cary, NC).
31
32
33
34
35
36
37
38
39

40 **RESULTS**

41
42
43 We included 171 patients with PF, of whom 137 were classified as having IPF, and 719
44
45 control subjects. Baseline characteristics are shown in Table 1. Among PF cases, the rate of
46
47 occupational exposure was higher in men than in women (80% vs. 52 %; $p < 0.001$). Men
48
49 also had higher smoking exposure. Ten years before the PF diagnosis, 90 (84%) men were
50
51 ever-smokers with a median 10 (IQR, 3 – 23) pack years, compared to 29 (45%) women with
52
53 a median 8 (IQR, 3 – 15) pack years. A similar difference was seen for IPF cases.
54
55
56
57
58
59
60

1
2
3 There was a significant interaction between smoking, occupational exposure and gender, and
4 the risk of oxygen-dependent PF (test of homogeneity, $p = 0.028$). The differences in effects
5 were similar for IPF (Table 2). Men with current or past smoking and occupational exposure
6 had markedly increased risk of PF, OR 4.6 (2.1 – 10.3), and IPF, OR 3.0 (1.3 – 6.5),
7 compared to non-exposed women (Table 2). Adjustment for differences in pack years
8 between men and women, in addition to the other covariates, did not affect the estimates.

9
10
11
12
13
14
15
16
17 There was a linear association between higher cumulative smoking exposure (up to ten years
18 before diagnosis) and increased risk of PF and IPF, OR 1.03 (95% CI, 1.01 – 1.04) per pack
19 year and OR 1.02 (95% CI, 1.01 – 1.04) per pack year, respectively. Compared to lower
20 levels of smoking (1 – 9 pack years), heavy smoking (≥ 20 pack years) was associated with an
21 increased risk of PF, OR 2.6 (95% CI, 1.4 – 4.9), and IPF, OR 2.5 (95% CI, 1.3 – 5.0), as
22 shown in Table 3. Using a 5-year time lag for smoking exposure instead of 10 years resulted
23 in similar estimates.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

39 DISCUSSION

40
41
42 The main findings are that 1) smoking was a risk determinant in the development of oxygen-
43 dependent pulmonary fibrosis and that this risk was amplified by male gender and
44 occupational exposure; 2) the association with smoking was dose-dependent, which may
45 support the theory of the causative role of smoking in the pathogenesis of severe pulmonary
46 fibrosis.
47
48
49
50
51
52

53
54 Our findings are consistent with reports of increased risk of IPF associated with smoking^{4-6 10}
55 and occupational exposures.^{4-7 9 12 14 16} A previous analysis using the present data set
56
57
58
59
60

1
2
3 showed that specific occupational factors associated with an increased risk of PF included
4 exposure to birds and wood dust.¹⁴ Studies of a possible dose-response correlation between
5 smoking and IPF have shown conflicting results, with two studies indicating a dose-dependent
6 effect^{5 6} and one study showing no dose correlation.¹⁷ The latter study, however, analyzed
7 only smoking status and the current smoking dose (cigarettes per day) and not cumulative
8 smoking exposure such as pack years.¹⁷ The present study extends the previous observations
9 by demonstrating that the association between smoking and severe pulmonary fibrosis is
10 dose-dependent and is modified by gender and occupational exposure.
11
12
13
14
15
16
17
18
19

20
21 A strength of the present study is that it included cases from a population-based prospective
22 register of patients starting LTOT in Sweden. Control subjects were randomly selected from
23 the general population. Previous studies using control subjects in hospitals may have yielded
24 biased estimates, as the risk of hospitalization is likely to be related to occupational factors
25 and smoking.^{4 7 9-11} We had detailed data on the temporality, dose and duration of smoking. In
26 contrast with previous studies, only exposure data up to ten years before the year of the PF
27 diagnosis was included in the analysis to avoid reverse causation and to allow for the time lag
28 between exposure to risk factors and the manifestation of clinical disease.
29
30
31
32
33
34
35
36
37
38

39 A possible limitation is that the self-reported exposure data could be influenced by recall bias.
40 The validity of the exposure classification is, however, supported by a high degree of
41 consistency between reported employment histories and occupational exposure to specific
42 agents.¹⁴ Secondly, the association between smoking and starting LTOT could be affected by
43 survivor bias, as smokers are likely to be at high risk of dying of other diseases, such as
44 cancer and cardiovascular disease, before they can develop severe IPF. Also, stopping
45 smoking is a mandatory criterion for starting LTOT. Both these potential biases would tend to
46 lower the number of smokers starting LTOT and our findings might thus underestimate the
47 association between smoking and oxygen-dependent PF. Thirdly, the IPF diagnosis could be
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 misclassified in some patients. The validity of the PF and IPF diagnoses was checked by a
4
5 respiratory physician using medical records, including available radiographic and histologic
6
7 data.¹⁴ Among idiopathic interstitial pneumonias, IPF is the most common condition and it is
8
9 associated with a high risk of progression to hypoxemic respiratory failure and death.^{1 18} Thus,
10
11 the prevalence of IPF is likely high in oxygen-dependent pulmonary fibrosis. We included the
12
13 PF cohort in the analysis, as it may be difficult to obtain a specific diagnosis in patients with
14
15 advanced pulmonary fibrosis at the clinic. Our results were consistent in both the PF and IPF
16
17 groups, which supports the validity of the present findings.
18
19

20
21 Mechanisms governing the relationship between smoking, gender, occupational exposure,
22
23 and the development of severe pulmonary fibrosis are unknown but likely involve complex
24
25 interactions between different environmental factors in genetically predisposed individuals.¹⁹
26
27 The adverse effect of smoking could in part be attributable to the development of concurrent
28
29 emphysema, which has been shown to predict hypoxemia and a poor prognosis in IPF.²⁰
30
31

32
33 For the clinician, this study identifies a group of male, heavy smokers with occupational
34
35 exposure to harmful substances, who have a greatly increased risk of developing severe
36
37 pulmonary fibrosis. In this group, interventions to help people reduce or stop smoking are a
38
39 top priority.
40
41

42
43 In conclusion, smoking is associated with a dose-dependent increase in oxygen-dependent
44
45 pulmonary fibrosis. The adverse effects of smoking are stronger in men and in people with
46
47 occupational exposure.
48
49

50 51 52 53 **ACKNOWLEDGEMENTS** 54 55 56 57 58 59 60

1
2
3 **Author contributions:** ME had full access to all the data in the study and takes full
4
5 responsibility for the integrity of the data and the accuracy of the data analysis. Conception
6
7 and design: KB, KN, GT, KT; Acquisition of data: TG, KB, KN, GT, KT; Analysis and
8
9 interpretation of data: ME, TG, NM, KT; Drafting the article: ME, TG, KT; Revising it for
10
11 important intellectual content and approval of the version to be published: ME, TG, KB, KN,
12
13 GT, NM, KT.
14
15

16
17 **Funding:** This study was funded by the Research Council of Blekinge, the Swedish National
18
19 Board of Health and Welfare, and the Swedish Heart-Lung Foundation.
20
21

22 **Conflicts of interest:** No conflicts of interest exist for the authors.
23
24

25 **Other contributions:** The authors thank Kerstin Ström for her invaluable help and inspiration
26
27 throughout the study process, and the doctors and nurses who cared for the patients.
28
29

30 **Data sharing statement:** Analysis code is available from the corresponding author. No
31
32 additional data is available.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

- 1 American Thoracic Society/European Respiratory Society International Multidisciplinary
2
3
4
5
6 Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the
7
8 American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by
9
10 the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. *Am J*
11
12 *Respir Crit Care Med* 2002;165:277-304.
- 13
14
15
16
17 2 Raghu G, Collard HR, Egan JJ et al. An official ATS/ERS/JRS/ALAT statement: idiopathic
18
19 pulmonary fibrosis: evidence-based guidelines for diagnosis and management. *American*
20
21 *Journal of Respiratory and Critical Care Medicine* 2011;183:788-824.
- 22
23
24 3 Navaratnam V, Fleming KM, West J et al. The rising incidence of idiopathic pulmonary fibrosis
25
26 in the U.K. *Thorax* 2011;66:462-7.
- 27
28 4 Iwai K, Mori T, Yamada N, Yamaguchi M, Hosoda Y. Idiopathic pulmonary fibrosis.
29
30 Epidemiologic approaches to occupational exposure. *American Journal of Respiratory and*
31
32 *Critical Care Medicine* 1994;150:670-5.
- 33
34 5 Hubbard R, Lewis S, Richards K, Johnston I, Britton J. Occupational exposure to metal or
35
36 wood dust and aetiology of cryptogenic fibrosing alveolitis. *Lancet* 1996;347:284-9.
- 37
38 6 Baumgartner KB, Samet JM, Stidley CA, Colby TV, Waldron JA. Cigarette smoking: a risk factor
39
40 for idiopathic pulmonary fibrosis. *American Journal of Respiratory and Critical Care Medicine*
41
42 1997;155:242-8.
- 43
44 7 Miyake Y, Sasaki S, Yokoyama T et al. Occupational and environmental factors and idiopathic
45
46 pulmonary fibrosis in Japan. *The Annals of occupational hygiene* 2005;49:259-65.
- 47
48 8 Scott J, Johnston I, Britton J. What causes cryptogenic fibrosing alveolitis? A case-control
49
50 study of environmental exposure to dust. *BMJ* 1990;301:1015-7.
- 51
52 9 Awadalla NJ, Hegazy A, Elmetwally RA, Wahby I. Occupational and environmental risk factors
53
54 for idiopathic pulmonary fibrosis in Egypt: a multicenter case-control study. *Int J Occup*
55
56 *Environ Med* 2012;3:107-16.
- 57
58
59
60

- 1
2
3 10 Garcia-Sancho Figueroa MC, Carrillo G, Perez-Padilla R et al. Risk factors for idiopathic
4 pulmonary fibrosis in a Mexican population. A case-control study. *Respir Med* 2010;104:305-
5
6 9.
7
8
9 11 Miyake Y, Sasaki S, Yokoyama T et al. Case-control study of medical history and idiopathic
10 pulmonary fibrosis in Japan. *Respirology* 2005;10:504-9.
11
12
13 12 Taskar VS, Coultas DB. Is idiopathic pulmonary fibrosis an environmental disease?
14
15 *Proceedings of the American Thoracic Society* 2006;3:293-8.
16
17
18 13 Strom K, Boe J. A national register for long-term oxygen therapy in chronic hypoxia:
19 preliminary results. *Eur Respir J* 1988;1:952-8.
20
21
22 14 Gustafson T, Dahlman-Hoglund A, Nilsson K, Strom K, Tornling G, Toren K. Occupational
23 exposure and severe pulmonary fibrosis. *Respir Med* 2007;101:2207-12.
24
25
26 15 Toren K, Jarvholm B, Brisman J, Hagberg S, Hermansson BA, Lillienberg L. Adult-onset asthma
27 and occupational exposures. *Scand J Work Environ Health* 1999;25:430-5.
28
29
30 16 Baumgartner KB, Samet JM, Coultas DB et al. Occupational and environmental risk factors for
31 idiopathic pulmonary fibrosis: a multicenter case-control study. Collaborating Centers. *Am J*
32
33 *Epidemiol* 2000;152:307-15.
34
35
36 17 Gribbin J, Hubbard R, Smith C. Role of diabetes mellitus and gastro-oesophageal reflux in the
37 aetiology of idiopathic pulmonary fibrosis. *Respir Med* 2009;103:927-31.
38
39
40 18 Bjoraker JA, Ryu JH, Edwin MK et al. Prognostic significance of histopathologic subsets in
41 idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 1998;157:199-203.
42
43
44 19 Macneal K, Schwartz DA. The genetic and environmental causes of pulmonary fibrosis. *Proc*
45
46 *Am Thorac Soc* 2012;9:120-5.
47
48
49 20 Mejia M, Carrillo G, Rojas-Serrano J et al. Idiopathic pulmonary fibrosis and emphysema:
50 decreased survival associated with severe pulmonary arterial hypertension. *Chest*
51
52 2009;136:10-5.
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

TABLES

Table 1. Patient characteristics

Characteristic	PF cases (n = 171)	IPF cases (n = 137)	Controls (n = 719)
Age	73.7 ± 9.5	74.2 ± 9.8	64.3 ± 13.7
Males, n (%)	107 (63)	86 (63)	337 (47)
Never-smokers, n (%)	52 (30)	44 (32)	344 (48)
Ex-smokers, n (%)	114 (67)	89 (65)	251 (35)
Current smokers, n (%)	5 (3)	4 (3)	124 (17)
Smoking history up to 10 years before PF diagnosis, n (%)	119 (70)	93 (68)	375 (52)
1 – 9 pack years	29 (17)	22 (16)	176 (24)
10 – 19 pack years	34 (20)	27 (20)	91 (13)
≥ 20 pack years	36 (21)	27 (20)	62 (9)
Occupational exposure, n (%)	119 (70)	93 (68)	397 (55)

Data presented as mean ± standard deviation unless otherwise specified.

Abbreviations: IPF, idiopathic pulmonary fibrosis; PF, pulmonary fibrosis.

Table 2. Effect of smoking on the adjusted risk of pulmonary fibrosis, according to gender and occupational exposure

	PF		IPF	
	Odds ratio (95% CI)		Odds ratio (95% CI)	
	Women	Men	Women	Men
No occupational exposure	1.10 (0.50 – 2.42)	1.97 (0.64 – 6.13)	1.12 (0.49 – 2.59)	1.44 (0.43 – 4.83)
Occupational exposure	1.10 (0.52 – 2.34)	4.63 (2.08 – 10.33)	1.32 (0.58 – 3.03)	2.96 (1.34 – 6.52)

Odds ratios (95% confidence interval) for the effect of smoking vs. no smoking on the risk of developing PF and IPF, estimated using Mantel Haenzel analysis controlled for year of birth and year of diagnosis. Smoking was defined as the presence of ever-smoking earlier than 10 years before the diagnosis.

Abbreviations: CI, confidence interval; IPF, idiopathic pulmonary fibrosis; PF, pulmonary fibrosis.

Table 3. Dose-response effect of smoking on the risk of severe pulmonary fibrosis

Smoking, pack years*	PF	IPF
	OR (95% CI)	OR (95% CI)
0	1	1
1 – 9	1.03 (0.62 – 1.70)	0.90 (0.52 – 1.57)
10 – 19	2.26 (1.35 – 3.80)	2.10 (1.20 – 3.68)
≥ 20	2.66 (1.56 – 4.55)	2.25 (1.26 – 4.02)

Odds ratios (ORs) for levels of smoking estimated using conditional logistic regression

adjusted for age and stratified for year of birth, year of diagnosis, gender and occupational exposure.

* Pack years of smoking up to 10 years before the year of PF diagnosis.

Abbreviations: IPF, idiopathic pulmonary fibrosis; PF, pulmonary fibrosis.

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of case-control studies

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	Title
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Yes
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Yes
Objectives	3	State specific objectives, including any prespecified hypotheses	Yes
Methods			
Study design	4	Present key elements of study design early in the paper	Yes
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Yes
Participants	6	(a) Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls	Yes
		(b) For matched studies, give matching criteria and the number of controls per case	Yes
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Yes
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Yes
Bias	9	Describe any efforts to address potential sources of bias	Yes
Study size	10	Explain how the study size was arrived at	Yes
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Yes
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Yes
		(b) Describe any methods used to examine subgroups and interactions	Yes
		(c) Explain how missing data were addressed	Yes
		(d) If applicable, explain how matching of cases and controls was addressed	Yes
		(e) Describe any sensitivity analyses	Yes
Results			

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Yes
		(b) Give reasons for non-participation at each stage	Yes
		(c) Consider use of a flow diagram	Yes
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Yes
		(b) Indicate number of participants with missing data for each variable of interest	Yes
Outcome data	15*	Report numbers in each exposure category, or summary measures of exposure	Yes
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Adjusted analysis presented, biased crude estimates will be added upon request from reviewers or editor.
		(b) Report category boundaries when continuous variables were categorized	Yes
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Yes
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Yes
Discussion			
Key results	18	Summarise key results with reference to study objectives	Yes
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Yes
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Yes
Generalisability	21	Discuss the generalisability (external validity) of the study results	Yes
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Yes

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

For peer review only



Effects of smoking, gender and occupational exposures on the risk of severe pulmonary fibrosis: a population based case-control study

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-004018.R1
Article Type:	Research
Date Submitted by the Author:	18-Nov-2013
Complete List of Authors:	Ekström, Magnus; Department of Clinical Sciences, Division of Respiratory Medicine & Allergology, Lund University, ; Department of Medicine, Blekinge Hospital, Gustafson, Torbjörn; Institution of Public Health and Clinical Medicine, Umeå University, Boman, Kurt; Institution of Public Health and Clinical Medicine, Umeå University, Nilsson, Kenneth; Respiratory Medicine Unit, Department of Medicine Solna, the Karolinska Institute and Karolinska University Hospital, Tornling, Göran; Respiratory Medicine Unit, Department of Medicine Solna, the Karolinska Institute and Karolinska University Hospital, Murgia, Nicola; Section for Occupational Medicine, Respiratory Diseases and Toxicology, University of Perugia, Toren, Kjell; Section for Occupational and Environmental Medicine, Institute of Medicine, Sahlgrenska Academy at the University of Gothenburg,
Primary Subject Heading:	Respiratory medicine
Secondary Subject Heading:	Epidemiology, Occupational and environmental medicine, Smoking and tobacco
Keywords:	Epidemiology < TROPICAL MEDICINE, Thoracic medicine < INTERNAL MEDICINE, Interstitial lung disease < THORACIC MEDICINE

SCHOLARONE™
Manuscripts

1
2
3 **Effects of smoking, gender and occupational exposure on the risk of severe pulmonary**
4 **fibrosis: a population based case-control study**
5
6

7
8 Magnus Ekström, MD, PhD^{1,2}; Torbjörn Gustafson, MD, PhD³; Kurt Boman, MD, PhD³;
9
10 Kenneth Nilsson, MD, PhD³; Göran Tornling, MD, PhD⁴; Nicola Murgia, MD⁵; Kjell Torén,
11
12 MD, FCCP, PhD⁶
13

14
15
16
17
18
19 ¹ Department of Clinical Sciences, Division of Respiratory Medicine & Allergology, Lund
20
21 University, SE-22100 Lund, Sweden
22

23
24 ² Department of Medicine, Blekinge Hospital, SE-371 85 Karlskrona, Sweden
25

26
27 ³ Institution of Public Health and Clinical Medicine, Umeå University, SE-901 85 Umeå,
28
29 Sweden
30

31
32 ⁴ Respiratory Medicine Unit, Department of Medicine Solna, the Karolinska Institute and
33
34 Karolinska University Hospital, SE-171 76 Stockholm, Sweden
35

36
37 ⁵ Section for Occupational Medicine, Respiratory Diseases and Toxicology, University of
38
39 Perugia, 06123 Perugia, Italy
40

41
42 ⁶ Section for Occupational and Environmental Medicine, Institute of Medicine, Sahlgrenska
43
44 Academy at the University of Gothenburg, SE-405 30 Gothenburg, Sweden
45

46
47 **Corresponding author:** Magnus Ekström, Department of Respiratory Medicine, Blekinge
48
49 Hospital, SE-371 85 Karlskrona, Sweden. E-mail: pmekstrom@gmail.com. Tel: +46
50
51 455731000.
52

53
54
55 **Keywords:** Pulmonary fibrosis; Smoking; Occupational exposure; Mortality; Gender
56
57
58
59
60

1
2
3 **Running title:** Interacting factors and severe pulmonary fibrosis
4
5

6 **Word count:** 2,206
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3 Word count of abstract: 197
4

5 **ABSTRACT**
6
7

8 **Objectives:** To estimate the effects of smoking, gender and occupational exposure on the risk
9
10 of developing severe pulmonary fibrosis (PF), including dose-response and interaction effects.
11

12
13 **Methods:** National case-control study of 171 patients (cases) starting long-term oxygen
14
15 therapy (LTOT) for PF in Sweden between February 1997 and April 2000, and 719 random
16
17 control subjects from the general population. Of cases, 137 had probable idiopathic
18
19 pulmonary fibrosis (IPF). The odds ratios (ORs) for smoking, gender, and occupational
20
21 exposure were estimated using Mantel-Haenzel analysis and conditional logistic regression,
22
23 controlling for age and year of diagnosis.
24
25

26
27 **Results:** The adverse effect of smoking was amplified by male gender and occupational
28
29 exposure, OR 4.6 ([95% confidence interval] 2.1 – 10.3) for PF, and OR 3.0 (1.3 – 6.5) for
30
31 IPF, compared to in non-exposed women. Higher cumulative smoking exposure was linearly
32
33 associated with increased risks. Compared to smoking less than ten pack-years, smoking ≥ 20
34
35 pack-years was associated with increased risk of PF and IPF, OR 2.6 (1.4 – 4.9) and OR 2.5
36
37 (1.3 – 5.0), respectively.
38
39

40
41 **Conclusion:** Smoking has a dose-related association with increased risk of severe PF. Men
42
43 with a history of smoking and occupational exposure is a particular risk group for developing
44
45 severe pulmonary fibrosis.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ARTICLE SUMMARY

Article focus

- Smoking, male gender and occupational exposures are proposed risk factors for developing severe idiopathic pulmonary disease (IPF), but data on the interplay between these factors are limited.
- This study aims to estimate the effects of smoking, gender and occupational exposure on the risk of developing severe IPF, including interactions and dose-response effects.

Key messages

- Smoking has a dose-response association with increased risk of severe IPF.
- The adverse effect of smoking is strongly amplified by male gender and occupational exposure. This study identifies men with a history of smoking and occupational exposures as a particular risk group for developing severe IPF.

Strengths and limitations

- Population-based case-control study of subjects developing oxygen-dependent pulmonary in Sweden with randomly selected controls from the general population.
- Analysis of detailed exposure data, accounting for confounders and lag time between exposure and disease.
- As the underlying etiology may be difficult to ascertain in patients with oxygen-dependent pulmonary fibrosis, IPF was defined through review of national administrative register data and individual medical records.

BACKGROUND

Pulmonary fibrosis (PF) constitutes a range of conditions that are either secondary to diseases or factors, such as systemic inflammatory disease and drug therapies, or primary, of which the most common is idiopathic pulmonary fibrosis (IPF).¹

IPF is a chronic, progressive, fibrosing interstitial lung disease with a high risk of rapid progression and mortality.² Median survival after diagnosis is approximately two years.² The incidence of IPF has increased over time, with marked regional differences suggesting the pathogenic role of various environmental and occupational exposures.³

The etiology of IPF remains unknown.² The majority of IPF patients are men with a history of current or past smoking.² Most case-control studies have suggested an association between smoking and an increased risk of IPF,⁴⁻⁷ although one study reported no such association.⁸

This inconsistency is most likely due to differences in study settings, the included covariates and, in some studies, the use of hospital patients as control subjects, which might have biased the smoking estimates.^{4 7 9-11} Occupational exposures, including metal, stone and wood dust, have been linked to higher risks of developing IPF.¹²

It is unknown if there are interactions between smoking, gender, and occupational exposure, and the risk of developing IPF. The only two studies which analyzed interactions reported a tendency towards an amplified IPF risk in patients with a history of smoking and occupational exposure, but the studies failed to establish statistically significant interactions.^{6,13} Moreover, it is unclear if smoking really is an etiologic factor for IPF, as studies included low numbers of patients, and data on whether there is a dose-dependent relation between smoking and the risk of IPF are limited.

1
2
3 The aim of the present nationwide case-control study was therefore to estimate the
4
5 associations between smoking, gender, occupational exposure, and the risk of developing
6
7 severe pulmonary fibrosis.
8
9

16 **METHODS**

19 This was a national, register-based case-control study. Patients starting long-term oxygen
20
21 therapy (LTOT) for PF between 1 February 1997 and 4 April 2000 in the national Swedevox
22
23 register were eligible for inclusion as cases. The Swedevox register covers some 85% of all
24
25 patients starting LTOT in Sweden.¹³ Details of the study design and a previous analysis using
26
27 the same data set have been published.¹⁴ Data was collected through an extensive postal
28
29 questionnaire on smoking, occupational exposure (including fibers, fumes, gas, mineral dust,
30
31 organic dust, and vapours) and diagnosis of PF. The questionnaire has been described in detail
32
33 elsewhere.¹⁵ Smoking data included the year of starting smoking, date of stopping smoking,
34
35 and the mean number of smoked cigarettes per day during each ten year period between ages
36
37 15 – 65 years, and the mean exposure after age 65.¹⁵ Occupational data included the presence,
38
39 start year, stop year and intensity (hours per week) for any occupational exposure, and
40
41 exposure to birds (both at work and at home), metal dust, and wood dust. Occupational
42
43 exposure was defined as any exposure ten or more years before the date of the PF diagnosis,
44
45 allowing for a ten year lag-time between exposures and developing the disease.
46
47
48
49

50
51 After the exclusion of patients who were incorrectly registered (n = 12; 5%) or did not
52
53 respond to the questionnaire (n=58; 24%), 171 PF cases were included in the analysis.
54
55
56
57
58
59
60

1
2
3 Patients with probable idiopathic pulmonary fibrosis (IPF cases, n = 137) were identified
4 through a review of each patient's medical record done independently by specialists in
5 respiratory medicine (KN, TG).¹⁴ High-resolution computed tomography (HRCT) was
6 performed in 41% of PF patients, CT in an additional 10%, and trans-bronchial and open lung
7 biopsy was performed in 6%, respectively. The IPF cohort excluded patients with an
8 identifiable or probable cause of PF: rheumatic or systemic inflammatory diseases (20% of PF
9 cases), pneumoconiosis (6%), medications or irradiation (2%).¹⁴
10
11
12
13
14
15
16
17
18

19 Control subjects were selected as a random sample (n = 1000) from the general population of
20 the same age range as the PF patients. Of the control subjects, 719 (72%) returned complete
21 exposure data and were included in the analysis.
22
23
24
25
26
27
28
29

30 **Ethics Statement**

31
32 All participants gave their informed consent to participate. The study was approved by all the
33 relevant ethics committees in Sweden, the Swedish National Board of Health and Welfare,
34 and the Data Inspection Board.
35
36
37
38
39
40
41
42

43 **Statistical Analysis**

44
45 Cases and control subjects were categorized according to year of birth (1906 – 1923, 1924 –
46 1936 or 1937 – 1969) and cases according to year they received their PF diagnosis (1968–
47 1986, 1987–1993 or 1994–1999). Control subjects were assigned a time point corresponding
48 to the year patients received their PF diagnosis, using a method described previously.^{14 15}
49
50
51
52

53 First, control subjects within each birth year group were assigned a random diagnosis year
54 group, weighted by the number of cases in each diagnosis year group. Then, the year of PF
55
56
57
58
59
60

1
2
3 diagnosis of each control subject was set to the mid-year of the corresponding year of the
4 patient group. Characteristics at baseline (the date the questionnaire was filled in) were
5 presented using frequencies and percentages for categorical variables. Continuous data were
6 presented using mean with standard deviation (SD) and median with range or interquartile
7 range (IQR) for variables with normal and skewed distribution, respectively.
8
9
10
11
12

13
14 Smoking status and cumulative smoking exposure, calculated as pack years ([mean number of
15 cigarettes per day] / 20 x [years of exposure]), were recorded up to 10 years prior to the date
16 of the PF diagnosis (a 10-year time lag), allowing time between smoke exposure and the
17 development of oxygen-dependent PF.
18
19
20
21
22

23
24 Associations between smoking and the risk of developing oxygen-dependent PF and IPF, and
25 the interactions between smoking, occupational exposure and gender were estimated and
26 reported using Mantel-Haenzel analysis, controlling for year of birth, year of diagnosis and
27 gender, as applicable. Interactions were also analyzed using conditional logistic regression,
28 stratified for year of birth, year of diagnosis, gender, with adjustment for age and pack-years
29 of smoking. All estimates were consistent between Mantel-Haenzel analysis and the
30 conditional logistic models.
31
32
33
34
35
36
37
38

39
40 Associations were expressed as odds ratios (ORs) with 95% confidence intervals (CIs).

41
42 Statistical significance was defined as a double-sided $p < 0.05$. Statistical analyses were
43 performed using Stata version 11.1 (StataCorp LP; College Station, TX) and SAS version 9.2
44 (SAS Institute, Inc., Cary, NC).
45
46
47
48
49
50
51
52
53
54
55

56 RESULTS

57
58
59
60

1
2
3 We included 171 patients with PF, of whom 137 were classified as having IPF, and 719
4
5 control subjects. Baseline characteristics are shown in Table 1. Among PF cases, the rate of
6
7 any occupational exposure was higher in men than in women (80% vs. 52 %; $p < 0.001$).
8
9 Men also had higher smoking exposure. Ten years before the PF diagnosis, 90 (84%) men
10
11 were ever-smokers with a median 10 (IQR, 3 – 23) pack years, compared to 29 (45%) women
12
13 with a median 8 (IQR, 3 – 15) pack years. A similar difference was seen for IPF cases.
14
15
16
17
18
19

20 **Interactions**

21
22
23 There was a significant interaction between smoking, occupational exposure and gender, and
24
25 the risk of developing oxygen-dependent PF (test of homogeneity, $p = 0.028$). The interaction
26
27 was similar in the IPF cohort (Table 2). Men with current or past smoking and occupational
28
29 exposure had markedly increased risk of PF, OR 4.6 (2.1 – 10.3), and IPF, OR 3.0 (1.3 – 6.5),
30
31 compared to non-exposed women (Table 2). Adjustment for differences in pack years
32
33 between men and women, in addition to the other covariates, did not affect the estimates.
34
35
36
37
38
39

40 **Dose-response effect**

41
42
43 There was a linear association between higher cumulative smoking exposure (up to ten years
44
45 before diagnosis) and increased risk of PF and IPF, OR 1.03 (95% CI, 1.01 – 1.04) per pack
46
47 year and OR 1.02 (95% CI, 1.01 – 1.04) per pack year, respectively. Compared to lower
48
49 levels of smoking (1 – 9 pack years), heavy smoking (≥ 20 pack years) was associated with an
50
51 increased risk of PF, OR 2.6 (95% CI, 1.4 – 4.9), and IPF, OR 2.5 (95% CI, 1.3 – 5.0), as
52
53 shown in Table 3. Using a 5-year time lag for smoking exposure instead of 10 years resulted
54
55 in similar estimates.
56
57
58
59
60

Subtypes of occupational exposure

The effect of occupational exposure seemed to be mediated partly through exposure to birds and wood dust. The risk of PF was increased by exposure to birds (OR 1.9; 95% CI, 1.0 – 3.7) and wood dust (OR 1.7; 95% CI, 1.0 – 3.0), controlling for age, gender, year of diagnosis, and smoking. There were no evidence of effects of inorganic dust (OR 1.3; 95% CI, 0.8 – 2.0) or metal dust (OR 1.1; 95% CI, 0.6 – 1.8). There were signs of interactions with smoking and gender for exposure to birds ($p = 0.021$) and wood dust ($p = 0.023$), respectively. Estimates were similar for the IPF cohort, except for a lower effect of bird exposure (OR 1.3; 95% CI, 0.6 – 2.8).

DISCUSSION

The main findings are that 1) smoking was a risk determinant in the development of oxygen-dependent pulmonary fibrosis and that this risk was amplified by male gender and occupational exposure; 2) the association with smoking was dose-dependent, which may support the theory of the causative role of smoking in the pathogenesis of severe pulmonary fibrosis.

Our findings are consistent with reports of increased risk of IPF associated with smoking^{4-6 10} and occupational exposures.^{4-7 9 12 14 16} A previous analysis using the present data set showed that specific occupational factors associated with an increased risk of PF included exposure to birds and wood dust.¹⁴ Studies of a possible dose-response correlation between smoking and IPF have shown conflicting results, with two studies indicating a dose-dependent

1
2
3 effect^{5 6} and one study showing no dose correlation.¹⁷ The latter study, however, analyzed
4
5 only smoking status and the current smoking dose (cigarettes per day) and not cumulative
6
7 smoking exposure such as pack years.¹⁷ The present study extends the previous observations
8
9 by demonstrating that the association between smoking and severe pulmonary fibrosis is
10
11 dose-dependent and is modified by gender and occupational exposure.
12
13

14
15 A strength of the present study is that it included cases from a population-based prospective
16
17 register of patients starting LTOT in Sweden. Control subjects were randomly selected from
18
19 the general population. Previous studies using control subjects in hospitals may have yielded
20
21 biased estimates, as the risk of hospitalization is likely to be related to occupational factors
22
23 and smoking.^{4 7 9-11} We had detailed data on the temporality, dose and duration of smoking. In
24
25 contrast with previous studies, only exposure data up to ten years before the year of the PF
26
27 diagnosis was included in the analysis to avoid reverse causation and to allow for the time lag
28
29 between exposure to risk factors and the manifestation of clinical disease.
30
31

32
33 A possible limitation is that the self-reported exposure data could be influenced by recall bias.
34
35 The validity of the exposure classification was, however, supported by a high degree of
36
37 consistency between reported employment histories and occupational exposure to specific
38
39 agents.¹⁴ Second, the association between smoking and starting LTOT could be affected by
40
41 survivor bias, as smokers are likely to be at high risk of dying of other smoke-related disease,
42
43 such as cancer and cardiovascular disease, before they can develop severe IPF. Also, stopping
44
45 smoking is a mandatory criterion for starting LTOT. Both these potential biases would tend to
46
47 lower the number of smokers starting LTOT and to underestimate the association between
48
49 smoking and oxygen-dependent PF. Third, the IPF diagnosis could be misclassified in some
50
51 patients, especially as the cohort was collected prior to the publication of main consensus
52
53 definition of IPF.¹ The validity of the PF and IPF diagnoses was checked by respiratory
54
55 physicians using medical records, including available radiographic and histologic data.¹⁴
56
57
58
59
60

1
2
3 Among idiopathic interstitial pneumonias, IPF is the most common condition and it is
4 associated with a high risk of progression to hypoxemic respiratory failure and death.^{1 18} Thus,
5 the prevalence of IPF is likely high in oxygen-dependent pulmonary fibrosis. It is possible
6 that we included patients with combined PF and emphysema, which may be present in up to
7 one third of IPF patients.¹⁹ Concurrent emphysema may constitute a smoking-related
8 comorbidity or a distinct IPF phenotype,¹⁹ and could explain, at least partly, the association
9 between smoking, male gender, and the development of severe IPF in the present study. We
10 included the PF cohort in the analysis, as it may be difficult to obtain a specific diagnosis in
11 patients with advanced pulmonary fibrosis in the clinic. Findings were similar in the PF and
12 IPF cohorts, which supports the validity of the analysis. Using national population based cases
13 and controls, the present findings likely have high applicability to severe PF in Swedish
14 clinical practice. The validity to other settings may be lower owing to differences in socio-
15 demographics factors, health care organization, and pattern of exposure.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

31
32 Mechanisms governing the relationship between smoking, gender, occupational exposure,
33 and the development of severe pulmonary fibrosis are unknown but likely involve complex
34 interactions between different environmental factors in genetically predisposed individuals.²⁰
35
36
37 The adverse effect of smoking could in part be attributable to the development of concurrent
38 emphysema, which has been associated with hypoxemia and earlier death in IPF.²¹
39
40
41
42
43

44 For the clinician, this study identifies a group of male, heavy smokers with occupational
45 exposure to harmful substances, who have a greatly increased risk of developing severe
46 pulmonary fibrosis. In this group, interventions to help people reduce or stop smoking are a
47 top priority.
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 In conclusion, smoking is associated with a dose-dependent increase in oxygen-dependent
4 pulmonary fibrosis. The adverse effects of smoking are stronger in men and in people with
5 occupational exposure.
6
7
8
9

10 11 12 13 **ACKNOWLEDGEMENTS**

14
15
16 **Author contributions:** ME had full access to all the data in the study and takes full
17 responsibility for the integrity of the data and the accuracy of the data analysis. Conception
18 and design: KB, KN, GT, KT; Acquisition of data: TG, KB, KN, GT, KT; Analysis and
19 interpretation of data: ME, TG, NM, KT; Drafting the article: ME, TG, KT; Revising it for
20 important intellectual content and approval of the version to be published: ME, TG, KB, KN,
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
GT, NM, KT.

Funding: This study was funded by the Research Council of Blekinge, the Swedish National
Board of Health and Welfare, and the Swedish Heart-Lung Foundation.

Conflicts of interest: No conflicts of interest exist for the authors.

Other contributions: The authors thank Kerstin Ström for her invaluable help and inspiration
throughout the study process, and the doctors and nurses who cared for the patients.

Data sharing statement: Analysis code is available from the corresponding author.

References

- 1 American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. *Am J Respir Crit Care Med* 2002;165:277-304.
- 2 Raghu G, Collard HR, Egan JJ et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. *American Journal of Respiratory and Critical Care Medicine* 2011;183:788-824.
- 3 Navaratnam V, Fleming KM, West J et al. The rising incidence of idiopathic pulmonary fibrosis in the U.K. *Thorax* 2011;66:462-7.
- 4 Iwai K, Mori T, Yamadaa N, Yamaguchi M, et al. Idiopathic pulmonary fibrosis. Epidemiologic approaches to occupational exposure. *American Journal of Respiratory and Critical Care Medicine* 1994;150:670-5.
- 5 Hubbard R, Lewis S, Richards K, et al. Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis. *Lancet* 1996;347:284-9.
- 6 Baumgartner KB, Samet JM, Stidley CA, Colby TV, Waldron JA. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. *American Journal of Respiratory and Critical Care Medicine* 1997;155:242-8.
- 7 Miyake Y, Sasaki S, Yokoyama T et al. Occupational and environmental factors and idiopathic pulmonary fibrosis in Japan. *The Annals of occupational hygiene* 2005;49:259-65.
- 8 Scott J, Johnston I, Britton J. What causes cryptogenic fibrosing alveolitis? A case-control study of environmental exposure to dust. *BMJ* 1990;301:1015-7.
- 9 Awadalla NJ, Hegazy A, Elmetwally RA, et al. Occupational and environmental risk factors for idiopathic pulmonary fibrosis in Egypt: a multicenter case-control study. *Int J Occup Environ Med* 2012;3:107-16.
- 10 Garcia-Sancho Figueroa MC, Carrillo G, Perez-Padilla R et al. Risk factors for idiopathic pulmonary fibrosis in a Mexican population. A case-control study. *Respir Med* 2010;104:305-9.
- 11 Miyake Y, Sasaki S, Yokoyama T et al. Case-control study of medical history and idiopathic pulmonary fibrosis in Japan. *Respirology* 2005;10:504-9.
- 12 Taskar VS, Coultas DB. Is idiopathic pulmonary fibrosis an environmental disease? *Proceedings of the American Thoracic Society* 2006;3:293-8.
- 13 Strom K, Boe J. A national register for long-term oxygen therapy in chronic hypoxia: preliminary results. *Eur Respir J* 1988;1:952-8.
- 14 Gustafson T, Dahlman-Hoglund A, Nilsson K, et al. Occupational exposure and severe pulmonary fibrosis. *Respir Med* 2007;101:2207-12.
- 15 Toren K, Jarvholm B, Brisman J, et al. Adult-onset asthma and occupational exposures. *Scand J Work Environ Health* 1999;25:430-5.
- 16 Baumgartner KB, Samet JM, Coultas DB et al. Occupational and environmental risk factors for idiopathic pulmonary fibrosis: a multicenter case-control study. Collaborating Centers. *Am J Epidemiol* 2000;152:307-15.
- 17 Gribbin J, Hubbard R, Smith C. Role of diabetes mellitus and gastro-oesophageal reflux in the aetiology of idiopathic pulmonary fibrosis. *Respir Med* 2009;103:927-31.
- 18 Bjoraker JA, Ryu JH, Edwin MK et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 1998;157:199-203.
- 19 Cottin V. The impact of emphysema in pulmonary fibrosis. *European Respiratory Review* 2013;22:153-157.
- 20 Macneal K, Schwartz DA. The genetic and environmental causes of pulmonary fibrosis. *Proc Am Thorac Soc* 2012;9:120-5.

- 21 Mejia M, Carrillo G, Rojas-Serrano J et al. Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. *Chest* 2009;136:10-5.

TABLES

Table 1. Patient characteristics

Characteristic	PF cases (n = 171)	IPF cases (n = 137)	Controls (n = 719)
Age	73.7 ± 9.5	74.2 ± 9.8	64.3 ± 13.7
Males, n (%)	107 (63)	86 (63)	337 (47)
Never-smokers, n (%)	52 (30)	44 (32)	344 (48)
Ex-smokers, n (%)	114 (67)	89 (65)	251 (35)
Current smokers, n (%)	5 (3)	4 (3)	124 (17)
Smoking exposure, n (%) *	119 (70)	93 (68)	375 (52)
1 – 9 pack years	29 (17)	22 (16)	176 (24)
10 – 19 pack years	34 (20)	27 (20)	91 (13)
≥ 20 pack years	36 (21)	27 (20)	62 (9)
Occupational exposure, n (%) *	119 (70)	93 (68)	397 (55)
Birds	16 (9)	11 (8)	33 (5)
Inorganic dust	55 (32)	40 (29)	164 (23)

Metal dust	35 (20)	27 (19)	119 (17)
Organic dust	67 (39)	52 (38)	182 (25)
Wood dust	32 (18)	25 (18)	57 (8)

Data presented as mean \pm standard deviation unless otherwise specified.

* Exposure earlier than 10 years before PF diagnosis (ten year lag time).

Abbreviations: IPF, idiopathic pulmonary fibrosis; PF, pulmonary fibrosis.

Table 2. Effect of smoking on the adjusted risk of pulmonary fibrosis, according to gender and occupational exposure

	PF		IPF	
	Odds ratio (95% CI)		Odds ratio (95% CI)	
	Women	Men	Women	Men
No occupational exposure	1.10 (0.50 – 2.42)	1.97 (0.64 – 6.13)	1.12 (0.49 – 2.59)	1.44 (0.43 – 4.83)
Occupational exposure	1.10 (0.52 – 2.34)	4.63 (2.08 – 10.33)	1.32 (0.58 – 3.03)	2.96 (1.34 – 6.52)

Odds ratios (95% confidence interval) for the effect of smoking vs. no smoking on the risk of developing PF and IPF, estimated using Mantel Haenzel analysis controlled for year of birth and year of diagnosis. Smoking was defined as the presence of ever-smoking earlier than 10 years before the diagnosis.

Abbreviations: CI, confidence interval; IPF, idiopathic pulmonary fibrosis; PF, pulmonary fibrosis.

Table 3. Dose-response effect of smoking on the risk of severe pulmonary fibrosis

Smoking, pack years*	PF	IPF
	OR (95% CI)	OR (95% CI)
0	1	1
1 – 9	1.03 (0.62 – 1.70)	0.90 (0.52 – 1.57)
10 – 19	2.26 (1.35 – 3.80)	2.10 (1.20 – 3.68)
≥ 20	2.66 (1.56 – 4.55)	2.25 (1.26 – 4.02)

Odds ratios (ORs) for levels of smoking estimated using conditional logistic regression adjusted for age and stratified for year of birth, year of diagnosis, gender and occupational exposure.

* Pack years of smoking up to 10 years before the year of PF diagnosis.

Abbreviations: IPF, idiopathic pulmonary fibrosis; PF, pulmonary fibrosis.

1
2
3
4
5
6
7 **Effects of smoking, gender and occupational exposure on the risk of severe pulmonary**
8 **fibrosis: a population based case-control study**
9

10 Magnus Ekström, MD, PhD^{1,2}; Torbjörn Gustafson, MD, PhD³; Kurt Boman, MD, PhD³;
11 Kenneth Nilsson, MD, PhD³; Göran Tornling, MD, PhD⁴; Nicola Murgia, MD⁵; Kjell Torén,
12 MD, FCCP, PhD⁶
13
14
15
16
17
18
19

20 ¹ Department of Clinical Sciences, Division of Respiratory Medicine & Allergology, Lund
21 University, SE-22100 Lund, Sweden
22
23

24 ² Department of Medicine, Blekinge Hospital, SE-371 85 Karlskrona, Sweden
25
26

27 ³ Institution of Public Health and Clinical Medicine, Umeå University, SE-901 85 Umeå,
28 Sweden
29
30

31 ⁴ Respiratory Medicine Unit, Department of Medicine Solna, the Karolinska Institute and
32 Karolinska University Hospital, SE-171 76 Stockholm, Sweden
33
34

35 ⁵ Section for Occupational Medicine, Respiratory Diseases and Toxicology, University of
36 Perugia, 06123 Perugia, Italy
37
38

39 ⁶ Section for Occupational and Environmental Medicine, Institute of Medicine, Sahlgrenska
40 Academy at the University of Gothenburg, SE-405 30 Gothenburg, Sweden
41
42
43

44 **Corresponding author:** Magnus Ekström, Department of Respiratory Medicine, Blekinge
45 Hospital, SE-371 85 Karlskrona, Sweden. E-mail: pmekstrom@gmail.com. Tel: +46
46 455731000.
47
48
49
50


51 **Keywords:** Pulmonary fibrosis; Smoking; Occupational exposure; Mortality; Gender
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Running title: Interacting factors and severe pulmonary fibrosis

Word count: 24,206865

For peer review only



Word count of abstract: 1978

ABSTRACT

Objectives: To estimate the effects of smoking, gender and occupational exposure on the risk of developing severe pulmonary fibrosis (PF), including dose-response and interaction effects.

Methods: National case-control study of 171 patients (cases) starting long-term oxygen therapy (LTOT) for PF in Sweden between February 1997 and April 2000, and 719 random control subjects from the general population. Of cases, 137 had probable idiopathic pulmonary fibrosis (IPF). The odds ratios (ORs) for smoking, gender, and occupational exposure were estimated using Mantel-Haenzel analysis and conditional logistic regression, controlling for age and year of diagnosis.

Results: The adverse effect of smoking was amplified by male gender and occupational exposure, OR 4.6 ([95% confidence interval] 2.1 – 10.3) for PF, and OR 3.0 (1.3 – 6.5) for IPF, compared to in non-exposed women. Higher cumulative smoking exposure was linearly associated with increased risks. Compared to smoking less than ten pack-years, smoking ≥ 20 pack-years was associated with increased risk of PF and IPF, OR 2.6 (1.4 – 4.9) and OR 2.5 (1.3 – 5.0), respectively.

Conclusion: Smoking has a dose-related association with increased risk of severe PF. Men with a history of smoking and occupational exposure is a particular risk group for developing severe pulmonary fibrosis.

ARTICLE SUMMARY

Article focus

- Smoking, male gender and occupational exposures are proposed risk factors for developing severe idiopathic pulmonary disease (IPF), but data on the interplay between these factors are limited.
- This study aims to estimate the effects of smoking, gender and occupational exposure on the risk of developing severe IPF, including interactions and dose-response effects.

Key messages

- Smoking has a dose-response association with increased risk of severe IPF.
- The adverse effect of smoking is strongly amplified by male gender and occupational exposure. This study identifies men with a history of smoking and occupational exposures as a particular risk group for developing severe IPF.

Strengths and limitations

- Population-based case-control study of subjects developing oxygen-dependent pulmonary in Sweden with randomly selected controls from the general population.
- Analysis of detailed exposure data, accounting for confounders and lag time between exposure and disease.
- As the underlying etiology may be difficult to ascertain in patients with oxygen-dependent pulmonary fibrosis, IPF was defined through review of national administrative register data and individual medical records.

BACKGROUND

Pulmonary fibrosis (PF) constitutes a range of conditions that are either secondary to diseases or factors, such as systemic inflammatory disease and drug therapies, or primary, of which the most common is idiopathic pulmonary fibrosis (IPF).¹

IPF is a chronic, progressive, fibrosing interstitial lung disease with a high risk of rapid progression and mortality.² Median survival after diagnosis is approximately two years.² The incidence of IPF has increased over time, with marked regional differences suggesting the pathogenic role of various environmental and occupational exposures.³

The etiology of IPF remains unknown.² The majority of IPF patients are men with a history of current or past smoking.² Most case-control studies have suggested an association between smoking and an increased risk of IPF,⁴⁻⁷ although one study reported no such association.⁸ This inconsistency is most likely due to differences in study settings, the included covariates and, in some studies, the use of hospital patients as control subjects, which might have biased the smoking estimates.^{4 7 9-11} Occupational exposures, including metal, stone and wood dust, have been linked to higher risks of developing IPF.¹²

It is unknown if there are interactions between smoking, gender, and occupational exposure, and the risk of developing IPF. The only two studies which analyzed interactions reported a tendency towards an amplified IPF risk in patients with a history of smoking and occupational exposure, but the studies failed to establish statistically significant interactions.^{6,13} Moreover, it is unclear if smoking really is an etiologic factor for IPF, as studies included low numbers of patients, and data on whether there is a dose-dependent relation between smoking and the risk of IPF are limited.

1
2
3
4
5
6
7 The aim of the present nationwide case-control study was therefore to estimate the
8 associations between smoking, gender, occupational exposure, and the risk of developing
9 severe pulmonary fibrosis.
10
11
12
13
14
15
16
17

18 METHODS

19
20 This was a national, register-based case-control study. Patients starting long-term oxygen
21 therapy (LTOT) for PF between 1 February 1997 and 4 April 2000 in the national Swedevox
22 register were eligible for inclusion as cases. The Swedevox register covers some 85% of all
23 patients starting LTOT in Sweden.¹³ Details of the study design and a previous analysis using
24 the same data set have been published.¹⁴ Data was collected through an extensive postal
25 questionnaire on smoking, occupational exposure (including fibers, fumes, gas, mineral dust,
26 organic dust, and vapours) and diagnosis of PF. The questionnaire has been described in detail
27 elsewhere.¹⁵ Smoking data included the year of starting smoking, date of stopping smoking,
28 and the mean number of smoked cigarettes per day during each ten year period between ages
29 15 – 65 years, and the mean exposure after age 65.¹⁵ Occupational data included the presence,
30 start year, stop year and intensity (hours per week) for any occupational exposure, and
31 exposure to birds (both at work and at home), metal dust, and wood dust. Occupational
32 exposure was defined as any exposure ten or more years before the date of the PF diagnosis,
33 allowing for a ten year lag-time between exposures and developing the disease.
34
35
36
37
38
39
40
41
42
43
44
45
46
47

48 After the exclusion of patients who were incorrectly registered (n = 12; 5%) or did not
49 respond to the questionnaire (n=58; 24%), 171 PF cases were included in the analysis.
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7 Patients with probable idiopathic pulmonary fibrosis (IPF cases, n = 137) were identified
8 through a review of each patient's medical record done independently by specialists in
9 respiratory medicine (KN, TG).¹⁴ High-resolution computed tomography (HRCT) was
10 performed in 41% of PF patients, CT in an additional 10%, and trans-bronchial and open lung
11 biopsy was performed in 6%, respectively. The IPF cohort excluded cases in the study
12 included only patients without with any identifiable or probable cause of PF: (rheumatic or
13 systemic inflammatory diseases (20% of PF cases), infection, pneumoconiosis (6%),
14 medications or, irradiation (2%), rheumatic or systemic inflammatory diseases_etc.)¹⁴
15
16
17
18
19
20
21
22

23 Control subjects were selected as a random sample (n = 1000) from the general population of
24 the same age range as the PF patients. Of the control subjects, 719 (72%) returned complete
25 exposure data and were included in the analysis.
26
27
28
29
30
31

32 **Ethics Statement**

33
34 All participants gave their informed consent to participate. The study was approved by all the
35 relevant ethics committees in Sweden, the Swedish National Board of Health and Welfare,
36 and the Data Inspection Board.
37
38
39
40
41
42

43 **Statistical Analysis**

44
45 Cases and control subjects were categorized according to year of birth (1906 – 1923, 1924 –
46 1936 or 1937 – 1969) and cases according to year they received their PF diagnosis (1968–
47 1986, 1987–1993 or 1994–1999). Control subjects were assigned a time point corresponding
48 to the year patients received their PF diagnosis, using a method described previously.^{14 15}
49
50
51
52
53
54 First, control subjects within each birth year group were assigned a random diagnosis year
55
56
57
58
59
60

1
2
3
4
5
6
7 group, weighted by the number of cases in each diagnosis year group. Then, the year of PF
8 diagnosis of each control subject was set to the mid-year of the corresponding year of the
9 patient group. Characteristics at baseline (the date the questionnaire was filled in) were
10 presented using frequencies and percentages for categorical variables. Continuous data were
11 presented using mean with standard deviation (SD) and median with range or interquartile
12 range (IQR) for variables with normal and skewed distribution, respectively.
13
14
15
16
17

18
19 Smoking status and cumulative smoking exposure, calculated as pack years ([mean number of
20 cigarettes per day] / 20 x [years of exposure]), were recorded up to 10 years prior to the date
21 of the PF diagnosis (a 10-year time lag), allowing time between smoke exposure and the
22 development of oxygen-dependent PF.
23
24
25
26

27 Associations between smoking and the risk of developing oxygen-dependent PF and IPF, and
28 the interactions between smoking, occupational exposure and gender were estimated and
29 reported using Mantel-Haenzel analysis, controlling for year of birth, year of diagnosis and
30 gender, as applicable. Interactions were also analyzed using conditional logistic regression,
31 stratified for year of birth, year of diagnosis, gender, with adjustment for age and pack-years
32 of smoking. All estimates were consistent between Mantel-Haenzel analysis and the
33 conditional logistic models.
34
35
36
37
38
39

40 Associations were expressed as odds ratios (ORs) with 95% confidence intervals (CIs).

41
42 Statistical significance was defined as a double-sided $p < 0.05$. Statistical analyses were
43 performed using Stata version 11.1 (StataCorp LP; College Station, TX) and SAS version 9.2
44 (SAS Institute, Inc., Cary, NC).
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

RESULTS

We included 171 patients with PF, of whom 137 were classified as having IPF, and 719 control subjects. Baseline characteristics are shown in Table 1. Among PF cases, the rate of any occupational exposure was higher in men than in women (80% vs. 52 %; $p < 0.001$).

Men also had higher smoking exposure. Ten years before the PF diagnosis, 90 (84%) men were ever-smokers with a median 10 (IQR, 3 – 23) pack years, compared to 29 (45%) women with a median 8 (IQR, 3 – 15) pack years. A similar difference was seen for IPF cases.

Interactions

There was a significant interaction between smoking, occupational exposure and gender, and the risk of developing oxygen-dependent PF (test of homogeneity, $p = 0.028$). The interaction differences in effects ~~was~~ ere similar ~~for in the~~ IPF cohort (Table 2). Men with current or past smoking and occupational exposure had markedly increased risk of PF, OR 4.6 (2.1 – 10.3), and IPF, OR 3.0 (1.3 – 6.5), compared to non-exposed women (Table 2).

Adjustment for differences in pack years between men and women, in addition to the other covariates, did not affect the estimates.

Dose-response effect

There was a linear association between higher cumulative smoking exposure (up to ten years before diagnosis) and increased risk of PF and IPF, OR 1.03 (95% CI, 1.01 – 1.04) per pack year and OR 1.02 (95% CI, 1.01 – 1.04) per pack year, respectively. Compared to lower levels of smoking (1 – 9 pack years), heavy smoking (≥ 20 pack years) was associated with an increased risk of PF, OR 2.6 (95% CI, 1.4 – 4.9), and IPF, OR 2.5 (95% CI, 1.3 – 5.0), as

Formatted: Font: Bold

Formatted: Font: Bold

Formatted: Font: Bold

1
2
3
4
5
6
7 shown in Table 3. Using a 5-year time lag for smoking exposure instead of 10 years resulted
8
9 in similar estimates.

10 11 12 13 Subtypes of occupational exposure

14
15
16 The effect of occupational exposure seemed to be mediated partly through exposure to birds
17
18 and wood dust. The risk of PF was increased by exposure to birds (OR 1.9; 95% CI, 1.0 – 3.7)
19
20 and wood dust (OR 1.7; 95% CI, 1.0 – 3.0), controlling for age, gender, year of diagnosis, and
21
22 smoking. There were no evidence of effects of inorganic dust (OR 1.3; 95% CI, 0.8 – 2.0) or
23
24 metal dust (OR 1.1; 95% CI, 0.6 – 1.8). There were signs of interactions with smoking and
25
26 gender for exposure to birds (p = 0.021) and wood dust (p = 0.023), respectively. Estimates
27
28 were similar for the IPF cohort, except for a lower effect of bird exposure (OR 1.3; 95% CI,
29
30 0.6 – 2.8).

Formatted: Font: Bold

Formatted: Font: Bold

31 32 33 34 35 36 37 **DISCUSSION**

38
39
40 The main findings are that 1) smoking was a risk determinant in the development of oxygen-
41
42 dependent pulmonary fibrosis and that this risk was amplified by male gender and
43
44 occupational exposure; 2) the association with smoking was dose-dependent, which may
45
46 support the theory of the causative role of smoking in the pathogenesis of severe pulmonary
47
48 fibrosis.

49
50 Our findings are consistent with reports of increased risk of IPF associated with smoking^{4-6 10}
51
52^{12 16} and occupational exposures.^{4-7 9 12 14 16} A previous analysis using the present data set

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

showed that specific occupational factors associated with an increased risk of PF included exposure to birds and wood dust.¹⁴ Studies of a possible dose-response correlation between smoking and IPF have shown conflicting results, with two studies indicating a dose-dependent effect^{5,6} and one study showing no dose ~~correlation~~-correlation.¹⁷ The latter study, however, analyzed only smoking status and the current smoking dose (cigarettes per day) and not cumulative smoking exposure such as pack years.¹⁷ The present study extends the previous observations by demonstrating that the association between smoking and severe pulmonary fibrosis is dose-dependent and is modified by gender and occupational exposure.

A strength of the present study is that it included cases from a population-based prospective register of patients starting LTOT in Sweden. Control subjects were randomly selected from the general population. Previous studies using control subjects in hospitals may have yielded biased estimates, as the risk of hospitalization is likely to be related to occupational factors and smoking.^{4,7,9-11} We had detailed data on the temporality, dose and duration of smoking. In contrast with previous studies, only exposure data up to ten years before the year of the PF diagnosis was included in the analysis to avoid reverse causation and to allow for the time lag between exposure to risk factors and the manifestation of clinical disease.

A possible limitation is that the self-reported exposure data could be influenced by recall bias. The validity of the exposure classification ~~is~~was, however, supported by a high degree of consistency between reported employment histories and occupational exposure to specific agents.¹⁴ ~~Secondly~~, the association between smoking and starting LTOT could be affected by survivor bias, as smokers are likely to be at high risk of dying of other smoke-related diseases, such as cancer and cardiovascular disease, before they can develop severe IPF. Also, stopping smoking is a mandatory criterion for starting LTOT. Both these potential biases would tend to lower the number of smokers starting LTOT ~~and our findings might thus~~and to underestimate the association between smoking and oxygen-dependent PF. ~~Thirdly~~, the IPF diagnosis could

1
2
3
4
5
6
7 be misclassified in some patients, especially as the cohort was collected prior to the
8 publication of main consensus definition of IPF.¹ The validity of the PF and IPF diagnoses
9 was checked by ~~a~~ respiratory physicians using medical records, including available
10 radiographic and histologic data.¹⁴ Among idiopathic interstitial pneumonias, IPF is the most
11 common condition and it is associated with a high risk of progression to hypoxemic
12 respiratory failure and death.¹⁸ Thus, the prevalence of IPF is likely high in oxygen-
13 dependent pulmonary fibrosis. It is possible that we included patients with combined PF and
14 emphysema, which may be present in up to one third of IPF patients.¹⁹ Concurrent
15 emphysema may constitute a smoking-related comorbidity or a distinct IPF phenotype,¹⁹ and
16 could explain, at least partly, the association between smoking, male gender, and the
17 development of severe IPF in the present study. We included the PF cohort in the analysis, as
18 it may be difficult to obtain a specific diagnosis in patients with advanced pulmonary fibrosis
19 ~~at in~~ the clinic. ~~Our results~~ Findings were similar ~~consistent~~ in ~~both~~ the PF and IPF
20 ~~groups~~ cohorts, which supports the validity of the ~~present analysis~~ findings. Using national
21 population based cases and controls, the present findings likely have high applicability to
22 severe PF in Swedish clinical practice. The validity to other settings may be lower owing to
23 differences in socio-demographics factors, health care organization, and pattern of exposure.
24
25 Mechanisms governing the relationship between smoking, gender, occupational exposure,
26 and the development of severe pulmonary fibrosis are unknown but likely involve complex
27 interactions between different environmental factors in genetically predisposed individuals.²⁰
28 The adverse effect of smoking could in part be attributable to the development of concurrent
29 emphysema, which has been associated ~~shown to predict~~ with hypoxemia ~~and a earlier~~
30 death ~~poor prognosis~~ in IPF.²¹
31
32 For the clinician, this study identifies a group of male, heavy smokers with occupational
33 exposure to harmful substances, who have a greatly increased risk of developing severe
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7 pulmonary fibrosis. In this group, interventions to help people reduce or stop smoking are a
8 top priority.
9

10
11 In conclusion, smoking is associated with a dose-dependent increase in oxygen-dependent
12 pulmonary fibrosis. The adverse effects of smoking are stronger in men and in people with
13 occupational exposure.
14
15
16
17
18
19

20 ACKNOWLEDGEMENTS

21
22
23 **Author contributions:** ME had full access to all the data in the study and takes full
24 responsibility for the integrity of the data and the accuracy of the data analysis. Conception
25 and design: KB, KN, GT, KT; Acquisition of data: TG, KB, KN, GT, KT; Analysis and
26 interpretation of data: ME, TG, NM, KT; Drafting the article: ME, TG, KT; Revising it for
27 important intellectual content and approval of the version to be published: ME, TG, KB, KN,
28 GT, NM, KT.
29
30
31
32
33
34

35 **Funding:** This study was funded by the Research Council of Blekinge, the Swedish National
36 Board of Health and Welfare, and the Swedish Heart-Lung Foundation.
37
38

39 **Conflicts of interest:** No conflicts of interest exist for the authors.
40
41

42 **Other contributions:** The authors thank Kerstin Ström for her invaluable help and inspiration
43 throughout the study process, and the doctors and nurses who cared for the patients.
44
45

46 **Data sharing statement:** Analysis code is available from the corresponding author. No
47 additional data is available.
48
49
50
51
52
53
54
55
56
57
58
59
60

References


- 1 American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. *Am J Respir Crit Care Med* 2002;165:277-304.
- 2 Raghu G, Collard HR, Egan JJ et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. *American Journal of Respiratory and Critical Care Medicine* 2011;183:788-824.
- 3 Navaratnam V, Fleming KM, West J et al. The rising incidence of idiopathic pulmonary fibrosis in the U.K. *Thorax* 2011;66:462-7.
- 4 Iwai K, Mori T, Yamada N, Yamaguchi M, Hosoda Y. Idiopathic pulmonary fibrosis. Epidemiologic approaches to occupational exposure. *American Journal of Respiratory and Critical Care Medicine* 1994;150:670-5.
- 5 Hubbard R, Lewis S, Richards K, Johnston I, Britton J. Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis. *Lancet* 1996;347:284-9.
- 6 Baumgartner KB, Samet JM, Stidley CA, Colby TV, Waldron JA. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. *American Journal of Respiratory and Critical Care Medicine* 1997;155:242-8.
- 7 Miyake Y, Sasaki S, Yokoyama T et al. Occupational and environmental factors and idiopathic pulmonary fibrosis in Japan. *The Annals of occupational hygiene* 2005;49:259-65.
- 8 Scott J, Johnston I, Britton J. What causes cryptogenic fibrosing alveolitis? A case-control study of environmental exposure to dust. *BMJ* 1990;301:1015-7.
- 9 Awadalla NJ, Hegazy A, Elmetwally RA, Wahby I. Occupational and environmental risk factors for idiopathic pulmonary fibrosis in Egypt: a multicenter case-control study. *Int J Occup Environ Med* 2012;3:107-16.
- 10 Garcia-Sancho Figueroa MC, Carrillo G, Perez-Padilla R et al. Risk factors for idiopathic pulmonary fibrosis in a Mexican population. A case-control study. *Respir Med* 2010;104:305-9.
- 11 Miyake Y, Sasaki S, Yokoyama T et al. Case-control study of medical history and idiopathic pulmonary fibrosis in Japan. *Respirology* 2005;10:504-9.
- 12 Taskar VS, Coultas DB. Is idiopathic pulmonary fibrosis an environmental disease? *Proceedings of the American Thoracic Society* 2006;3:293-8.
- 13 Strom K, Boe J. A national register for long-term oxygen therapy in chronic hypoxia: preliminary results. *Eur Respir J* 1988;1:952-8.
- 14 Gustafson T, Dahlman-Hoglund A, Nilsson K, Strom K, Tornling G, Toren K. Occupational exposure and severe pulmonary fibrosis. *Respir Med* 2007;101:2207-12.
- 15 Toren K, Jarvholm B, Brisman J, Hagberg S, Hermansson BA, Lillienberg L. Adult-onset asthma and occupational exposures. *Scand J Work Environ Health* 1999;25:430-5.
- 16 Baumgartner KB, Samet JM, Coultas DB et al. Occupational and environmental risk factors for idiopathic pulmonary fibrosis: a multicenter case-control study. Collaborating Centers. *Am J Epidemiol* 2000;152:307-15.
- 17 Gribbin J, Hubbard R, Smith C. Role of diabetes mellitus and gastro-oesophageal reflux in the aetiology of idiopathic pulmonary fibrosis. *Respir Med* 2009;103:927-31.
- 18 Bjoraker JA, Ryu JH, Edwin MK et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 1998;157:199-203.
- 19 Cottin V. The impact of emphysema in pulmonary fibrosis. *European Respiratory Review* 2013;22:153-157.
- 20 Macneal K, Schwartz DA. The genetic and environmental causes of pulmonary fibrosis. *Proc Am Thorac Soc* 2012;9:120-5.

Formatted: Swedish (Sweden)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

21 Meja M, Carrillo G, Rojas-Serrano J et al. Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. *Chest* 2009;136:10-5.

For peer review only



TABLES

Table 1. Patient characteristics

Characteristic	PF cases (n = 171)	IPF cases (n = 137)	Controls (n = 719)
Age	73.7 ± 9.5	74.2 ± 9.8	64.3 ± 13.7
Males, n (%)	107 (63)	86 (63)	337 (47)
Never-smokers, n (%)	52 (30)	44 (32)	344 (48)
Ex-smokers, n (%)	114 (67)	89 (65)	251 (35)
Current smokers, n (%)	5 (3)	4 (3)	124 (17)
Smoking history exposure up to 10 years before PF diagnosis, n (%) [*]	119 (70)	93 (68)	375 (52)
1 – 9 pack years	29 (17)	22 (16)	176 (24)
10 – 19 pack years	34 (20)	27 (20)	91 (13)
≥ 20 pack years	36 (21)	27 (20)	62 (9)
Occupational exposure, n (%) [*]	119 (70)	93 (68)	397 (55)
Birds	16 (9)	11 (8)	33 (5)

Formatted: Centered

<u>Inorganic dust</u>	<u>55 (32)</u>	<u>40 (29)</u>	<u>164 (23)</u>
<u>Metal dust</u>	<u>35 (20)</u>	<u>27 (19)</u>	<u>119 (17)</u>
<u>Organic dust</u>	<u>67 (39)</u>	<u>52 (38)</u>	<u>182 (25)</u>
<u>Wood dust</u>	<u>32 (18)</u>	<u>25 (18)</u>	<u>57 (8)</u>

Formatted: Centered

Formatted: Centered

Data presented as mean \pm standard deviation unless otherwise specified.

* Exposure earlier than 10 years before PF diagnosis (ten year lag time).

Abbreviations: IPF, idiopathic pulmonary fibrosis; PF, pulmonary fibrosis.

Table 2. Effect of smoking on the adjusted risk of pulmonary fibrosis, according to gender and occupational exposure

	PF		IPF	
	Odds ratio (95% CI)		Odds ratio (95% CI)	
	Women	Men	Women	Men
No occupational exposure	1.10 (0.50 – 2.42)	1.97 (0.64 – 6.13)	1.12 (0.49 – 2.59)	1.44 (0.43 – 4.83)
Occupational exposure	1.10 (0.52 – 2.34)	4.63 (2.08 – 10.33)	1.32 (0.58 – 3.03)	2.96 (1.34 – 6.52)

Odds ratios (95% confidence interval) for the effect of smoking vs. no smoking on the risk of developing PF and IPF, estimated using Mantel Haenzel analysis controlled for year of birth and year of diagnosis. Smoking was defined as the presence of ever-smoking earlier than 10 years before the diagnosis.

Abbreviations: CI, confidence interval; IPF, idiopathic pulmonary fibrosis; PF, pulmonary fibrosis.

Table 3. Dose-response effect of smoking on the risk of severe pulmonary fibrosis

Smoking, pack years*	PF	IPF
	OR (95% CI)	OR (95% CI)
0	1	1
1 – 9	1.03 (0.62 – 1.70)	0.90 (0.52 – 1.57)
10 – 19	2.26 (1.35 – 3.80)	2.10 (1.20 – 3.68)
≥ 20	2.66 (1.56 – 4.55)	2.25 (1.26 – 4.02)

Odds ratios (ORs) for levels of smoking estimated using conditional logistic regression adjusted for age and stratified for year of birth, year of diagnosis, gender and occupational exposure.

* Pack years of smoking up to 10 years before the year of PF diagnosis.

Abbreviations: IPF, idiopathic pulmonary fibrosis; PF, pulmonary fibrosis.

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *case-control studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Title
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Yes
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Yes
Objectives	3	State specific objectives, including any prespecified hypotheses	Yes
Methods			
Study design	4	Present key elements of study design early in the paper	Yes
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Yes
Participants	6	(a) Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls	Yes
		(b) For matched studies, give matching criteria and the number of controls per case	Yes
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Yes
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Yes
Bias	9	Describe any efforts to address potential sources of bias	Yes
Study size	10	Explain how the study size was arrived at	Yes
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Yes
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Yes
		(b) Describe any methods used to examine subgroups and interactions	Yes
		(c) Explain how missing data were addressed	Yes
		(d) If applicable, explain how matching of cases and controls was addressed	Yes
		(e) Describe any sensitivity analyses	Yes
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Yes
		(b) Give reasons for non-participation at each stage	Yes
		(c) Consider use of a flow diagram	Yes
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Yes
		(b) Indicate number of participants with missing data for each variable of interest	Yes
Outcome data	15*	Report numbers in each exposure category, or summary measures of exposure	Yes
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Adjusted analysis presented, biased crude estimates will be added upon request from reviewers or editor.
		(b) Report category boundaries when continuous variables were categorized	Yes
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Yes
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Yes
Discussion			
Key results	18	Summarise key results with reference to study objectives	Yes
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Yes
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Yes
Generalisability	21	Discuss the generalisability (external validity) of the study results	Yes
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Yes

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

1
2
3
4
5 **Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE
6 checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at
7 <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

For peer review only